A Phase 3, Double Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 ug in 4-7 year old Children with Peanut Allergy.
The objective of this study is to assess the efficacy and safety of DBV712 250 ug to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12 month treatment period by epicutaneous immunotherapy.
PI Dr. Heather Cassell
A Biorepository of Food Allergic patients
The objective of this study is to make quality biospecimens and associated clinical data available for research studies related to advancing food allergy and improving care for patients. There are no primary endpoints for this biobank; endpoints will be specific to research projects that utilize the samples/data contained in the biobank. Projects may investigate the biology, etiology, manifestations, progression, risk factors, genetic underpinnings, and treatment of food allergy.
PI Dr. Heather Cassell
Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects with Peanut Allergy and to Explore Preliminary Signals of its Efficacy.
The primary objective is to evaluate the safety and tolerability of VLP peanut in healthy subjects and in peanut allergic subjects via subcutaneous administration. The secondary objective is to evaluate the occurrence of influenza like symptoms following subcutaneous administration of VLP peanut in healthy subjects and peanut allergic subjects.
PI Dr. Heather Cassell
If interested call (520) 833-3856